NASDAQ: ZLAB
Zai Lab Ltd Stock

$27.97+0.91 (+3.36%)
Updated Feb 12, 2025
ZLAB Price
$27.97
Fair Value Price
N/A
Market Cap
$2.79B
52 Week Low
$13.48
52 Week High
$36.60
P/E
-10.36x
P/B
4.17x
P/S
6.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$355.75M
Earnings
-$270.85M
Gross Margin
63.2%
Operating Margin
-75.76%
Profit Margin
-76.1%
Debt to Equity
0.48
Operating Cash Flow
-$174M
Beta
1.12
Next Earnings
Feb 25, 2025
Ex-Dividend
N/A
Next Dividend
N/A

ZLAB Overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ZLAB's potential to beat the market

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ZLAB
Ranked
Unranked of 557

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ZLAB news, forecast changes, insider trades & much more!

ZLAB News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ZLAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ZLAB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ZLAB is good value based on its book value relative to its share price (4.17x), compared to the US Biotechnology industry average (4.78x)
P/B vs Industry Valuation
ZLAB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ZLAB due diligence checks available for Premium users.

Valuation

ZLAB price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-10.36x
Industry
-144.01x
Market
37.75x

ZLAB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
4.17x
Industry
4.78x
ZLAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ZLAB's financial health

Profit margin

Revenue
$102.3M
Net Income
-$41.7M
Profit Margin
-40.7%
ZLAB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ZLAB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$985.3M
Liabilities
$317.7M
Debt to equity
0.48
ZLAB's short-term assets ($860.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZLAB's short-term assets ($860.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZLAB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ZLAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$26.8M
Investing
-$29.9M
Financing
$42.2M
ZLAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ZLAB vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ZLAB$2.79B+3.36%-10.36x4.17x
VCELB$2.77B-2.59%800.29x10.74x
MRUSC$2.76B+0.37%-10.19x3.92x
MLTXD$2.83B+2.41%-34.86x5.79x
FOLDC$2.85B-0.21%-28.09x15.96x

Zai Lab Stock FAQ

What is Zai Lab's quote symbol?

(NASDAQ: ZLAB) Zai Lab trades on the NASDAQ under the ticker symbol ZLAB. Zai Lab stock quotes can also be displayed as NASDAQ: ZLAB.

If you're new to stock investing, here's how to buy Zai Lab stock.

What is the 52 week high and low for Zai Lab (NASDAQ: ZLAB)?

(NASDAQ: ZLAB) Zai Lab's 52-week high was $36.60, and its 52-week low was $13.48. It is currently -23.58% from its 52-week high and 107.49% from its 52-week low.

How much is Zai Lab stock worth today?

(NASDAQ: ZLAB) Zai Lab currently has 996,087,670 outstanding shares. With Zai Lab stock trading at $27.97 per share, the total value of Zai Lab stock (market capitalization) is $2.79B.

Zai Lab stock was originally listed at a price of $27.93 in Sep 20, 2017. If you had invested in Zai Lab stock at $27.93, your return over the last 7 years would have been 0.14%, for an annualized return of 0.02% (not including any dividends or dividend reinvestments).

How much is Zai Lab's stock price per share?

(NASDAQ: ZLAB) Zai Lab stock price per share is $27.97 today (as of Feb 12, 2025).

What is Zai Lab's Market Cap?

(NASDAQ: ZLAB) Zai Lab's market cap is $2.79B, as of Feb 13, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Zai Lab's market cap is calculated by multiplying ZLAB's current stock price of $27.97 by ZLAB's total outstanding shares of 996,087,670.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.